Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 2;15(4):R71.
doi: 10.1186/ar4248.

Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome

Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome

Susan Lester et al. Arthritis Res Ther. .

Abstract

Introduction: The aim of this study was to examine the association between functional polymorphisms in the pro-inflammatory P2X7 receptor and the Ro/La autoantibody response in primary Sjögren's syndrome (pSS).

Methods: Twelve functional P2RX7 polymorphisms were genotyped in 114 pSS patients fulfilling the Revised American-European Consensus Criteria for pSS, and 136 controls. Genotyping of the A1405G (rs2230912) polymorphism was performed on a replication cohort consisting of 281 pSS patients and 534 controls. P2X7 receptor function in lymphocytes and monocytes was assessed by measurement of ATP-induced ethidium+ uptake. Serum IL-18 levels were determined by ELISA.

Results: The minor allele of P2RX7 A1405G is a tag for a common haplotype associated with gain in receptor function, as assessed by ATP-induced ethidium+ uptake. A positive association between 1405G and anti-Ro±La seropositive pSS patients was observed in Cohort 1. Although not replicated in Cohort 2, there was a consistent, significant, negative epistatic interaction effect with HLA-DR3 in seropositive pSS patients from both cohorts, thereby implicating this gain of function variant in the pathogenesis of pSS. Serum IL-18 was elevated in seropositive pSS patients, but was not influenced by P2RX7 A1405G.

Conclusions: The P2RX7 1405G gain-of-function haplotype may be a risk factor for seropositive pSS in a subset of subjects who do not carry HLA risk alleles, but has no effect in subjects who do (epistasis). Potential mechanisms relate to autoantigen exposure and inflammatory cytokine expression. The observed elevation of IL-18 levels is consistent with P2X7 receptor activation in seropositive pSS patients. Collectively these findings implicate P2X7 receptor function in the pathogenesis of pSS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Common (>5% frequency) P2RX7 haplotypes identified in the study population. Grey squares represent the major alleles and black squares the minor alleles, for each single nucleotide polymorphism. Numbering of polymorphisms are based on the original mRNA sequence [Y09561.1; GenBank]. Six major haplotypes were identified with a combined frequency of 70%.
Figure 2
Figure 2
Human peripheral blood mononuclear cells were analysed for ATP-induced ethidium uptake using time-resolved flow cytometry. Monocytes were identified by an anti-CD14 APC antibody and T lymphocytes were identified by an anti-CD3-PE antibody. Ethidium uptake (25 μM) was measured in response to P2X7 receptor stimulation by 1mM ATP. (A) and (C) are representative ethidium uptake curves from genotyped individuals. (B) and (D) are scattergrams of collated data from 5 to 18 subjects from each genotype group (number of subjects shown in brackets) with ATP-induced ethidium uptake calculated from the slope of the linear portion of the uptake plot over 1 minute. *P < 0.05 from one-way analysis of variance with Dunnett's post hoc test.
Figure 3
Figure 3
Boxplots of serum IL-18 levels (pg/mL) in controls (n = 36), autoantibody negative pSS (n = 18), and autoantibody positive primary Sjögren's syndrome (pSS) (n = 54). Serum IL-18 levels were significantly different between the three groups (P = 0.0003, Kruskal-Wallis test), and highest in autoantibody-positive pSS.

Similar articles

Cited by

References

    1. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;15:554–558. doi: 10.1136/ard.61.6.554. - DOI - PMC - PubMed
    1. Nordmark G, Alm GV, Ronnblom L. Mechanisms of Disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol. 2006;15:262–269. doi: 10.1038/ncprheum0173. - DOI - PubMed
    1. Rischmueller M, Lester S, Chen Z, Champion G, Van Den Berg R, Beer R, Coates T, McCluskey J, Gordon T. HLA class II phenotype controls diversification of the autoantibody response in primary Sjogren's syndrome (pSS) Clin Exp Immunol. 1998;15:365–371. doi: 10.1046/j.1365-2249.1998.00504.x. - DOI - PMC - PubMed
    1. Lester S, McLure C, Williamson J, Bardy P, Rischmueller M, Dawkins RL. Epistasis between the MHC and the RCA alpha block in primary Sjogren syndrome. Ann Rheum Dis. 2008;15:849–854. doi: 10.1136/ard.2007.075044. - DOI - PMC - PubMed
    1. Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM. HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012;15:281–287. doi: 10.1016/j.autrev.2011.10.002. - DOI - PubMed

Publication types